Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

A panelist discusses how the phase 2 ELECTRA trial studies elacestrant in combination with ribociclib as first-line therapy for ER+/HER2– advanced breast cancer in postmenopausal women.

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

The most frequently used standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer patients consists of a CDK4/6 ...

Camizestrant with Kisqali is effective and tolerable for ER-positive/HER2-negative advanced breast cancer, with a median PFS of 8.1 months for both doses. Objective ...

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients ...

ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. Results as of September 25, 2024 ...

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.

Kisqali (ribociclib), a CDK4/6 inhibitor, has made significant strides in the treatment of HR-positive, HER2-negative early breast cancer, although several follow-up studies are being conducted to ...

Basel, December 10, 2024 – Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali ® (ribociclib) that underscore the extended efficacy ...